Characteristics of patients and prognostic factors of response to rEPO at week 12 according to IWG 2000 criteria (N=403)
| . | Patients no. (%) . | Overall response, % . | Major response, % . | Minor response, % . | Overall response versus no response* . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis . | Multivariate analysis† . | |||||||||
| OR . | 95% CI . | P . | OR . | 95% CI . | P . | |||||
| Age at diagnosis, y | ||||||||||
| Younger than 70 | 150 (37) | 54 | 36 | 18 | 1 | — | — | 1 | — | — |
| 70 or older | 253 (63) | 67 | 44 | 23 | 1.6 | 1.0-2.4 | .03 | 1.4 | 0.9-2.3 | .13 |
| Sex | ||||||||||
| Male | 224 (56) | 61 | 38 | 23 | 1 | — | — | — | — | — |
| Female | 179 (44) | 64 | 46 | 18 | 1.2 | 0.8-1.7 | .47 | — | — | — |
| FAB | ||||||||||
| RA | 143 (36) | 69 | 53 | 16 | 1 | — | — | — | — | — |
| RARS | 142 (35) | 62 | 39 | 23 | 0.8 | 0.5-1.3 | — | — | — | — |
| RAEB less than 10 | 92 (23) | 56 | 33 | 23 | 0.6 | 0.4-1.0 | — | — | — | — |
| RAEB 10 or more | 26 (6) | 34 | 15 | 19 | 0.2 | 0.1-0.6 | .009 | — | — | — |
| WHO | ||||||||||
| RA | 60 (15) | 68 | 54 | 14 | 1 | — | — | 1 | — | — |
| RCMD | 68 (17) | 72 | 54 | 18 | 1.2 | 0.6-2.6 | — | 1.2 | 0.6-2.7 | — |
| RARS | 83 (21) | 59 | 40 | 19 | 0.7 | 0.3-1.3 | — | 0.7 | 0.3-1.4 | — |
| RCMD-RS | 57 (14) | 70 | 37 | 33 | 1.2 | 0.5-2.6 | — | 1.5 | 0.7-3.6 | — |
| RAEB-1 | 91 (23) | 56 | 33 | 23 | 0.6 | 0.3-1.3 | — | 0.9 | 0.4-1.8 | — |
| RAEB-2 | 26 (6) | 34 | 15 | 19 | 0.2 | 0.1-0.6 | — | 0.8 | 0.2-2.7 | — |
| 5q− syndrome | 18 (4) | 50 | 50 | 0 | 0.5 | 0.2-1.4 | .02 | 0.6 | 0.2-1.9 | .38 |
| Karyotype | ||||||||||
| Poor | 19 (5) | 43 | 21 | 22 | 1 | — | — | — | — | — |
| Good | 261 (65) | 63 | 43 | 20 | 2.9 | 1.3-6.2 | — | — | — | — |
| Intermediate | 66 (16) | 63 | 38 | 25 | 2.1 | 0.8-5.5 | — | — | — | — |
| NA | 57 (14) | 61 | 40 | 21 | 2.3 | 1.0-5.6 | .05 | — | — | — |
| Multilineage dysplasia | ||||||||||
| No | 180 (45) | 61 | 36 | 25 | 1 | — | — | — | — | — |
| Yes | 223 (55) | 63 | 46 | 17 | 1.1 | 0.8-1.7 | .52 | — | — | — |
| BM blasts | ||||||||||
| 5 or more | 105 (26) | 53 | — | — | 1 | — | — | — | — | — |
| Less than 5 | 298 (74) | 66 | 48 | 18 | 1.7 | 1.1-2.7 | .02 | — | — | — |
| EPO level, IU/L | ||||||||||
| More than 200 | 92 (23) | 42 | 37 | 25 | 1 | — | — | 1 | — | — |
| 200 or less | 248 (62) | 69 | 52 | 17 | 2.9 | 1.8-4.7 | — | 2.0 | 1.2-3.5 | — |
| NA | 63 (15) | 63 | 33 | 30 | 2.3 | 1.2-4.4 | <.001 | 2.1 | 1.0-4.2 | .03 |
| IPSS | ||||||||||
| Int-2 and high | 43 (11) | 36 | 17 | 19 | 1 | — | — | 1 | — | — |
| Low and int-1 | 303 (75) | 65 | 47 | 18 | 3.6 | 1.8-7.0 | — | 2.5 | 1.0-6.4 | .05 |
| NA | 57 (14) | 3.5 | 1.5-7.9 | .001 | 2.2 | 0.8-6.1 | .14 | |||
| RBC transfusion before rEPO treatment | ||||||||||
| No | 182 (45) | 76 | 60 | 16 | 1 | — | — | 1 | — | — |
| Yes | 221 (55) | 51 | 27 | 24 | 0.3 | 0.2-0.5 | <.001 | 0.4 | 0.2-0.6 | <.001 |
| Addition of G-CSF | ||||||||||
| No | 271 (67) | 66 | 46 | 20 | 1 | — | — | 1 | — | — |
| Yes | 132 (33) | 58 | 34 | 24 | 0.7 | 0.5-1.1 | .17 | 0.8 | 0.5-1.3 | .46 |
| Interval from diagnosis, mo | ||||||||||
| 6 or more | 198 (49) | 59 | 35 | 24 | 1 | — | — | 1 | — | — |
| Fewer than 6 | 205 (50) | 66 | 47 | 19 | 1.4 | 0.9-2.04 | .13 | 1.4 | 0.9-2.0 | .13 |
| . | Patients no. (%) . | Overall response, % . | Major response, % . | Minor response, % . | Overall response versus no response* . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis . | Multivariate analysis† . | |||||||||
| OR . | 95% CI . | P . | OR . | 95% CI . | P . | |||||
| Age at diagnosis, y | ||||||||||
| Younger than 70 | 150 (37) | 54 | 36 | 18 | 1 | — | — | 1 | — | — |
| 70 or older | 253 (63) | 67 | 44 | 23 | 1.6 | 1.0-2.4 | .03 | 1.4 | 0.9-2.3 | .13 |
| Sex | ||||||||||
| Male | 224 (56) | 61 | 38 | 23 | 1 | — | — | — | — | — |
| Female | 179 (44) | 64 | 46 | 18 | 1.2 | 0.8-1.7 | .47 | — | — | — |
| FAB | ||||||||||
| RA | 143 (36) | 69 | 53 | 16 | 1 | — | — | — | — | — |
| RARS | 142 (35) | 62 | 39 | 23 | 0.8 | 0.5-1.3 | — | — | — | — |
| RAEB less than 10 | 92 (23) | 56 | 33 | 23 | 0.6 | 0.4-1.0 | — | — | — | — |
| RAEB 10 or more | 26 (6) | 34 | 15 | 19 | 0.2 | 0.1-0.6 | .009 | — | — | — |
| WHO | ||||||||||
| RA | 60 (15) | 68 | 54 | 14 | 1 | — | — | 1 | — | — |
| RCMD | 68 (17) | 72 | 54 | 18 | 1.2 | 0.6-2.6 | — | 1.2 | 0.6-2.7 | — |
| RARS | 83 (21) | 59 | 40 | 19 | 0.7 | 0.3-1.3 | — | 0.7 | 0.3-1.4 | — |
| RCMD-RS | 57 (14) | 70 | 37 | 33 | 1.2 | 0.5-2.6 | — | 1.5 | 0.7-3.6 | — |
| RAEB-1 | 91 (23) | 56 | 33 | 23 | 0.6 | 0.3-1.3 | — | 0.9 | 0.4-1.8 | — |
| RAEB-2 | 26 (6) | 34 | 15 | 19 | 0.2 | 0.1-0.6 | — | 0.8 | 0.2-2.7 | — |
| 5q− syndrome | 18 (4) | 50 | 50 | 0 | 0.5 | 0.2-1.4 | .02 | 0.6 | 0.2-1.9 | .38 |
| Karyotype | ||||||||||
| Poor | 19 (5) | 43 | 21 | 22 | 1 | — | — | — | — | — |
| Good | 261 (65) | 63 | 43 | 20 | 2.9 | 1.3-6.2 | — | — | — | — |
| Intermediate | 66 (16) | 63 | 38 | 25 | 2.1 | 0.8-5.5 | — | — | — | — |
| NA | 57 (14) | 61 | 40 | 21 | 2.3 | 1.0-5.6 | .05 | — | — | — |
| Multilineage dysplasia | ||||||||||
| No | 180 (45) | 61 | 36 | 25 | 1 | — | — | — | — | — |
| Yes | 223 (55) | 63 | 46 | 17 | 1.1 | 0.8-1.7 | .52 | — | — | — |
| BM blasts | ||||||||||
| 5 or more | 105 (26) | 53 | — | — | 1 | — | — | — | — | — |
| Less than 5 | 298 (74) | 66 | 48 | 18 | 1.7 | 1.1-2.7 | .02 | — | — | — |
| EPO level, IU/L | ||||||||||
| More than 200 | 92 (23) | 42 | 37 | 25 | 1 | — | — | 1 | — | — |
| 200 or less | 248 (62) | 69 | 52 | 17 | 2.9 | 1.8-4.7 | — | 2.0 | 1.2-3.5 | — |
| NA | 63 (15) | 63 | 33 | 30 | 2.3 | 1.2-4.4 | <.001 | 2.1 | 1.0-4.2 | .03 |
| IPSS | ||||||||||
| Int-2 and high | 43 (11) | 36 | 17 | 19 | 1 | — | — | 1 | — | — |
| Low and int-1 | 303 (75) | 65 | 47 | 18 | 3.6 | 1.8-7.0 | — | 2.5 | 1.0-6.4 | .05 |
| NA | 57 (14) | 3.5 | 1.5-7.9 | .001 | 2.2 | 0.8-6.1 | .14 | |||
| RBC transfusion before rEPO treatment | ||||||||||
| No | 182 (45) | 76 | 60 | 16 | 1 | — | — | 1 | — | — |
| Yes | 221 (55) | 51 | 27 | 24 | 0.3 | 0.2-0.5 | <.001 | 0.4 | 0.2-0.6 | <.001 |
| Addition of G-CSF | ||||||||||
| No | 271 (67) | 66 | 46 | 20 | 1 | — | — | 1 | — | — |
| Yes | 132 (33) | 58 | 34 | 24 | 0.7 | 0.5-1.1 | .17 | 0.8 | 0.5-1.3 | .46 |
| Interval from diagnosis, mo | ||||||||||
| 6 or more | 198 (49) | 59 | 35 | 24 | 1 | — | — | 1 | — | — |
| Fewer than 6 | 205 (50) | 66 | 47 | 19 | 1.4 | 0.9-2.04 | .13 | 1.4 | 0.9-2.0 | .13 |